Published • loading... • Updated
CVS Caremark expands biosimilar adoption through formulary updates
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CVS Caremark expands biosimilar adoption through formulary updates
WOONSOCKET, R.I. – CVS Health announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including changes effective July 1, 2026, that will prefer interchangeable biosimilars over select reference brands.What changes are CVS Caremark making to its formulary?Effective July 1, 2026, CVS Caremark will implement targeted updates to its most common c…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
